Literature DB >> 2370178

Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy.

C D Wendt1, L J Peters, L Delclos, K K Ang, W H Morrison, M H Maor, K T Robbins, R M Byers, L S Carlson, M J Oswald.   

Abstract

From January 1963 through December 1979, 103 patients with Stage T1N0 and T2N0 squamous cell carcinomas of the oral tongue were treated with definitive radiotherapy. The primary was Stage T1 in 18 patients and T2 in 85 patients. Therapy to the primary consisted of interstitial therapy only in 18 patients, 16-37 Gy in 2.4-4.0 Gy fractions followed by interstitial therapy to doses of 38-55 Gy in 31 patients, external therapy of 40-50 Gy with interstitial therapy of 20-40 Gy in 46 patients, and external beam only to doses of 45-82 Gy in 8 patients. Follow-up ranged from 2 to 290 months (median 159 months). Five of the 8 patients treated with external therapy alone and 6 of the 18 patients treated with interstitial therapy failed at the primary site. In those patients treated with a combination of external and interstitial therapy the 2-year local control rate was 92% for patients treated with external therapy to doses of less than 40 Gy combined with a moderately high dose of brachytherapy, compared with 65% for patients who received external therapy to doses of greater than or equal to 40 Gy with lower brachytherapy doses (p = .01). Conversely the risk of failure in the neck was directly related to the dose delivered by external beam therapy. In field recurrence occurred in 44% of patients receiving no therapy to the neck. 27% in those receiving less than 40 Gy, and 11% in those patients with neck treatment to greater than or equal to 40 Gy. Eleven of 87 (13%) of patients who were at risk for complications for greater than or equal to 24 months developed severe complications; severe complications were more likely to occur in the group who received most of their therapy with external beam irradiation. These data show that a high dose of interstitial therapy is necessary to secure optimum local control of early primary tongue cancer. Because of the high frequency of moderate to severe late complications in this series we have adopted a policy of initial surgery for most oral tongue cancers with postoperative radiotherapy if indicated by pathological features predictive of a high rate of local-regional failure.

Entities:  

Mesh:

Year:  1990        PMID: 2370178     DOI: 10.1016/0360-3016(90)90299-y

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Head and neck cancer: an evolving treatment paradigm.

Authors:  David M Cognetti; Randal S Weber; Stephen Y Lai
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

2.  [A phase-I/II study on the local hyperthermia of cervical N2/N3 lymph node metastases].

Authors:  H Stahl; P Wust; R Graf; J Löffel; J Bier; H Riess; V Jahnke; R Felix
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

Review 3.  [Combined modality approaches in the treatment of head and neck cancer patients].

Authors:  C Simon; P K Plinkert
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

Review 4.  Oral cancer treatment.

Authors:  Terry A Day; Betsy K Davis; M Boyd Gillespie; John K Joe; Megan Kibbey; Bonnie Martin-Harris; Brad Neville; Mary S Richardson; Steven Rosenzweig; Anand K Sharma; Michelle M Smith; Stacy Stewart; Robert K Stuart
Journal:  Curr Treat Options Oncol       Date:  2003-02

5.  Brachytherapy of stage II mobile tongue carcinoma. Prediction of local control and QOL.

Authors:  Sayako Oota; Hitoshi Shibuya; Ryo-ichi Yoshimura; Hiroshi Watanabe; Masahiko Miura
Journal:  Radiat Oncol       Date:  2006-07-12       Impact factor: 3.481

6.  IMRT in oral cavity cancer.

Authors:  Gabriela Studer; Roger A Zwahlen; Klaus W Graetz; Bernard J Davis; Christoph Glanzmann
Journal:  Radiat Oncol       Date:  2007-04-12       Impact factor: 3.481

7.  Clinical outcome of high-dose-rate interstitial brachytherapy in patients with oral cavity cancer.

Authors:  Sung Uk Lee; Kwan Ho Cho; Sung Ho Moon; Sung Weon Choi; Joo Yong Park; Tak Yun; Sang Hyun Lee; Young Kyung Lim; Chi Young Jeong
Journal:  Radiat Oncol J       Date:  2014-12-30

8.  High-dose-rate interstitial brachytherapy in early stage oral tongue cancer - 15 year experience from a tertiary care institute.

Authors:  Anshuma Bansal; Sushmita Ghoshal; Arun S Oinam; Suresh Chander Sharma; Bhaswanth Dhanireddy; Rakesh Kapoor
Journal:  J Contemp Brachytherapy       Date:  2016-02-29

9.  Pulsed dose rate brachytherapy as the boost in combination with external beam irradiation in base of tongue cancer. Long-term results from a uniform clinical series.

Authors:  Bengt Johansson; Leif Karlsson; Johan Reizenstein; Mathias von Beckerath; Lennart Hardell; Jan Persliden
Journal:  J Contemp Brachytherapy       Date:  2011-03-31

10.  Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer.

Authors:  Shumei Murakami; Rinus G Verdonschot; Naoya Kakimoto; Iori Sumida; Masateru Fujiwara; Kazuhiko Ogawa; Souhei Furukawa
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.